The Pharma Letter Biotechnology_Petri DishBIOTECHNOLOGY looks at news relating to biotech companies, their financial performance, licensing, research and merger & acquisition activities. Read wide ranging reports from around the globe, backed by a massive archive from which developments in different areas can be tracked. At this time of new legislation and activities in the area of “biosimilars: or “biogenerics” approvals, which have progressed more in Europe and are likely to impact the huge US market quite soon, watching this area will be an important aspect for subscribers and those active in the sector.

Latest Pharma Letter Articles

Biotechnology

features_upload

BioSante reveals positive leukemia vaccine results, sending the stock soaring

12 March 2010

USA-based BioSante Pharmaceuticals saw its shares leap 17% to $2.00 in early trading yesterday,

0 Comments

Transgene signs billion dollar deal with Novartis for TG4010 cancer vaccine option, but still disappoints investors

11 March 2010

Transgene has signed an exclusive option agreement with Swiss drug major Novartis for the development

0 Comments

Korea’s Celltrion develops of broad spectrum human MAb against major flu viruses (H1N1 and H5N1)

11 March 2010

infection, which neutralize a broad spectrum of influenza viruses, including pandemic H1N1

0 Comments

Antisense Pharma gets added patent protection for trabedersen until 2026; raises 13 million euros

11 March 2010

The European Patent Office has granted German biopharmaceutical company Antisense Pharma additional

0 Comments

Abbott Labs bids $722 for Facet to enhances its biotech R&D pipeline, including daclizumab

10 March 2010

US health care major Abbott Laboratories has signed a definitive agreement for Abbott to acquire

0 Comments

InterMune leaps 62% after US FDA advisory backs the firm’s pirfenidone for idiopathic pulmonary fibrosis

10 March 2010

On a day that saw Nasdaq trading of US biotechnology firm InterMune’s shares halted as regulators

0 Comments